Incyte (INCY) closed at $120.97 on November 13, 2026, down 0.6% from the previous close, on volume of 882,507 shares (30-day average 1,737,300).
Data as of November 13, 2026.
13-Nov-2026
| # | Date | Strategy | Legs | Contracts |
|---|---|---|---|---|
| 1 | Oct 28, 2026 | Call Spread | 20-Nov-26115 : 130 C | 1,562 |
| 2-3 | The next 2 largest trades are for Premium members. Start a 7-day free trial | |||
Ranked by contracts: multi-leg trades of 200 or more contracts on one day, through Nov 13, 2026. See the 10 largest for 30, 60 and 90 days
Buy Rating Maintained on INCA033989’s Disease-Modifying Potential; Price Target Unchanged at $143
TipRanks (Sun, 15-Nov 9:25 AM ET)
Incyte won't move ahead with phase 3 trial of ovarian cancer asset
Seeking Alpha News (Fri, 13-Nov 5:09 PM ET)
Incyte Discontinues Planned Phase 3 Ovarian Cancer Study
TipRanks (Fri, 13-Nov 4:35 PM ET)
Business Wire (Tue, 10-Nov 7:00 AM ET)
Incyte to Present New Data Highlighting Progress Across its Hematology Portfolio at ASH 2026
Business Wire (Wed, 4-Nov 9:00 AM ET)
Incyte to Present at Upcoming Investor Conferences
Business Wire (Wed, 4-Nov 8:00 AM ET)
Market Chameleon (Thu, 29-Oct 5:44 AM ET)
Incyte Reports Third Quarter 2026 Financial Results and Provides Business Updates
Business Wire (Thu, 29-Oct 7:00 AM ET)
Incyte Highlights New Data Advancing its Gastrointestinal Cancer Portfolio at ESMO 2026
Business Wire (Mon, 26-Oct 9:45 AM ET)
Genmab and Incyte Announce Clinical Trial Collaboration in Metastatic Colorectal Cancer
Business Wire (Sat, 24-Oct 7:01 AM ET)
Incyte focuses on the discovery and development of small-molecule drugs. The firm's leading drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis and 2022 for vitiligo. Incyte's pipeline includes an array of oncology and dermatology programs.
Incyte trades on the NASDAQ stock market under the symbol INCY.
As of November 13, 2026, INCY stock price declined to $120.97 with 882,507 million shares trading.
INCY has a beta of 0.05, meaning it tends to be less sensitive to market movements. INCY has a correlation of 0.00 to the broad based SPY ETF.
INCY has a market cap of $24.66 billion. This is considered a Large Cap stock.
Last quarter Incyte reported $2 billion in Revenue and -$3.60 earnings per share. This beat revenue expectation by $87 million and exceeded earnings estimates by $.35.
In the last 3 years, INCY traded as high as $132.60 and as low as $50.35.
The top ETF exchange traded funds that INCY belongs to (by Net Assets): VTI, VOO, VB, IVV, VBK.
INCY has outperformed the market in the last year with a price return of +14.8% while the SPY ETF gained +13.4%. INCY has also outperformed the stock market ETF in the last 3 month and 2 week periods returning +0.4% and +0.5%, respectively, while the SPY returned -2.8% and -0.2%, respectively.
INCY support price is $118.63 and resistance is $124.77 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that INCY shares will trade within this expected range on the day.
